Cardiovascular disease is a leading contributor to morbidity and mortality, with over 17 million deaths occurring annually worldwide. Risk increases in adults over the age of 60, and in part is attributable to our inherited genetic makeup.
Cardiovascular disease – which includes coronary heart disease, cerebrovascular disease, peripheral artery disease, and atherosclerosis – is heavily influenced by factors such as insulin resistance, hypertension, dyslipidemia, inflammation, and coagulation properties. Many of these factors can be mitigated by lifestyle changes including smoking cessation, increasing aerobic exercise, and eating a well-balanced diet, which can reduce the risk of catastrophic events such as myocardial infarction, or ischemic and hemorrhagic stroke.
However, in some cases, particularly where family history of cardiovascular disease is prevalent, medications are needed to better manage health outcomes. In some patients, lifestyle and medication are still not enough, and greater intervention is necessary.
The Kashi Cardiac Health Panel focuses on eight genetic markers affecting hypertension, total cholesterol, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, thrombotic risk, homocysteinemia, insulin resistance, and statin-induced myopathy risk.
Strong candidates for the Kashi Cardiac Health Panel include patients with:
- Treatment-resistant hypertension
- Poor control over cholesterol levels
- Personal history of angina, DVT, PE, CHF, MI or CVA
- Introduction of new statin medications
- Family history of cardiovascular disease
- Stroke or heart disease in the young
- Idiopathic cardiovascular disease
Tests Included in the Cardiac Health Panel
GENETIC MARKERS EFFECT ON CARDIAC HEALTH ApoE Impacts management of cholesterol levels and risk of heart attack, stroke, hypertension, and coronary disease Factor II (Prothrombin) Affects the body’s ability to form blood clots which is tied to the risk of many cardiovascular-related health outcomes Factor V Enhances body’s coagulability which leads to thromboembolisms MTHFR Contributes to increased levels of homocysteine, a known risk factor for heart disease, atherosclerosis, and peripheral neuropathy 9p21 Associated with cellular growth and proliferation in relation to atherosclerosis, arterial stiffness and coronary artery disease eNOS/NOS3 Influences nitric oxide levels leading to risk of endothelial dysfunction, and many subsequent cardiovascular effects SLCO1B1*5 Modulates the body’s ability to metabolize statin medications, which are commonly prescribed to improve cholesterol AGT Key to maintaining blood pressure, patients who carry this mutation may be at an increased risk of developing hypertension
We will send you the test kit with 3 buccal swabs. You need to send it back to Invivo Clinical via guaranteed 1 pm next day delivery at your own cost. The results come back to us and we will send them to you via email.
If you like to discuss the results we can do this in a separate consultation with Dr Frey.